NVO vs. UTHR: Novo Nordisk vs. United Therapeutics Stock Comparison

Company Profile

Novo Nordisk (NVO) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NVO is classified in Pharmaceuticals while UTHR is classified in Biotechnology.

United Therapeutics (UTHR) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Novo Nordisk (NVO) is heavily traded at around 12.11M shares per day, whereas United Therapeutics (UTHR) sees a more moderate 694.55K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Novo Nordisk (NVO) at 58.38% and United Therapeutics (UTHR) at 19.13% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Novo Nordisk (NVO) at 33.92% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Novo Nordisk (NVO) at 40.05% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Novo Nordisk (NVO) at 6.43% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Novo Nordisk (NVO) at 1.77% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Only one side’s leverage can be read here: Novo Nordisk (NVO) carries debt-to-equity ratio of 0.62 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

Financial Strength Metrics

Dividends

United Therapeutics (UTHR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

United Therapeutics (UTHR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while United Therapeutics (UTHR) at 21.22 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while United Therapeutics (UTHR) at 7.51 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Novo Nordisk (NVO) at 5.43 and United Therapeutics (UTHR) at 3.80 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics